Circulating Tumor DNA for Early Response Assessment in Primary Central Nervous System Lymphoma Treated with First Line Curative Therapy

What this Trial Is About

Researchers are conducting an international, prospective, multicenter trial to study circulating tumor DNA (ctDNA) for early response evaluation in patients with primary central nervous system lymphoma (PCNSL) undergoing first-line standard of care therapy with curative intent. The study also aims to assess clinical features, quality of life, neurological status, and outcomes of newly diagnosed PCNSL patients in Nordic countries. Samples of tumor tissue, cerebrospinal fluid, and plasma will be collected to identify new prognostic and predictive biomarkers. Eligible patients will receive standard first-line therapies such as the MATRix regimen combined with high-dose chemotherapy and autologous stem cell transplantation, depending on local practice. Treatment responses will be evaluated using the International PCNSL Collaborative Group (IPCG) criteria, and MRI images will be centrally reviewed to discover additional biomarkers. The trial involves collecting diagnostic and response assessment data to better understand treatment effects. During the study, participants will undergo assessments including ctDNA measurement six months after starting therapy, clinical evaluations, health-related quality of life questionnaires, neurological examinations, and MRI scans. The researchers will monitor treatment response and safety, aiming to improve prognostic tools and patient outcomes. Participation involves providing informed consent and attending scheduled visits for sample collection and clinical follow-up.

CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)